CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
